Related Experiment Video
Updated: May 10, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
Published on: September 22, 2011
Systematic identification of genomic hotspots for high-yield protein production in CHO cells
Minouk Lee1, Sung-Hyuk Han2, Dongseok Kim1
1School of Chemical Engineering, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419, Republic of Korea.
Abstract:
The efficient and stable production of therapeutic proteins in Chinese hamster ovary (CHO) cells hinges on robust cell line development (CLD). Traditional methods relying on random transgene integration often result in clonal variability, requiring extensive and resource-intensive screening. To address this limitation, we established a systematic, multiomics-driven framework that integrates 202 RNA-sequencing datasets and whole-genome sequencing data to identify genomic "hotspot" loci for precise and high-yield transgene integration. From an initial pool of 20 candidate loci, 5 top-performing hotspots were validated using site-specific integration in CHO-DG44 cells via the CRISPR/Cas9 system with Recombinase-mediated cassette exchange (RMCE). These genomic hotspots achieved 2.2- to 15.0-fold higher relative specific productivity compared to previously known controls (Fer1L4 and Locus1 sites), across multiple therapeutic proteins, including a lysosomal storage disorder-related enzyme and an Immunoglobulin G (IgG)-related monoclonal antibody (mAb) expression. This study offers a transformative approach to CLD, achieving significant improvements in productivity, genomic stability, and efficiency, as well as paving the way for enhanced biopharmaceutical manufacturing.
Insights
Researchers identified specific genomic "hotspot" loci for precise transgene integration in Chinese hamster ovary (CHO) cells. This systematic approach significantly enhances therapeutic protein production and stability, improving biopharmaceutical manufacturing efficiency.
Area of Science:
- Biotechnology
- Genomics
- Cell Line Development
Background:
- Efficient and stable production of therapeutic proteins relies on robust Chinese hamster ovary (CHO) cell line development (CLD).
- Traditional methods using random transgene integration lead to clonal variability and extensive screening.
- Need for improved methods for high-yield, stable transgene integration in CHO cells.
Purpose of the Study:
- To establish a systematic, multiomics-driven framework for identifying genomic loci for precise and high-yield transgene integration.
- To validate identified genomic hotspots for site-specific integration in CHO cells.
- To enhance therapeutic protein production and genomic stability in biopharmaceutical manufacturing.
Main Methods:
- Integrated 202 RNA-sequencing and whole-genome sequencing datasets to identify genomic "hotspot" loci.
- Validated 5 top-performing hotspots using site-specific integration in CHO-DG44 cells.
- Employed CRISPR/Cas9 and Recombinase-mediated cassette exchange (RMCE) for precise integration.
Main Results:
- Identified and validated 5 high-performing genomic hotspots for transgene integration.
- Achieved 2.2- to 15.0-fold higher relative specific productivity compared to controls.
- Demonstrated improved productivity and genomic stability across multiple therapeutic proteins, including enzymes and Immunoglobulin G (IgG) monoclonal antibodies (mAbs).
Conclusions:
- A transformative, multiomics-driven framework significantly improves CHO cell line development.
- Precise transgene integration at validated genomic hotspots enhances therapeutic protein production efficiency and stability.
- This approach paves the way for enhanced biopharmaceutical manufacturing processes.
Related Concept Videos
Cell Specific Gene Expression
DNA Microarrays
Heterochromatin
Constitutive heterochromatin: It is a highly compact region of chromatin that is mostly concentrated in the centromere and telomere. Unlike euchromatin, the amino acid at 9th...
Cell Specific Gene Expression

